Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression

FASEB Journal

Volumn 14, Issue 15, 2000, Pages 2532-2539

  Miao, H Q ^a   Lee, P ^a   Lin, H ^a   Soker, S ^a   Klagsbrun, M ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Motility; Prostate carcinoma; VEGF; VEGF receptors

Indexed keywords

DOXYCYCLINE; NEUROPILIN; NEUROPILIN 1; TETRACYCLINE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; BASAL CELL; CANCER; CANCER GROWTH; CARCINOMA CELL; CELL MOTILITY; CONTROLLED STUDY; GENE OVEREXPRESSION; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; TUMOR VOLUME;

ANIMALIA;

EID: 0033674846     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.00-0250com     Document Type: Article

References (48)

1. Angiogenesis in cancer, vascular, rheumatoid and other disease
2. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
3. Molecular angiogenesis
4. The hallmarks of cancer
5. Vascular permeability, factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis
6. Vascular endothelial growth factor (VEGF) and its receptors
7. Clinical applications of angiogenic growth factors and their inhibitors
8. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
9. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo
10. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
11. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
12. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
13. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate
14. Identification of a natural soluble form of the vascular endothelial growth factor receptor. FLT-1, and its heterodimerization with KDR
15. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein
16. Ischemia-driven angiogenesis
17. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor
18. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
19. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor
20. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development
21. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain
22. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
23. Inhibition of vascular endothelial growth factor (VGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165
24. Growth-associated expression of a membrane protein, neuropilin, in Xenopus optic nerve fibers
25. Developmentally regulated expression of a cell surface protein, neuropilin, in the mouse nervous system
26. Neuropilin is a semaphorin III receptor
27. Neuropilin is a receptor for the axonal chemorepellent Semaphorin III
28. Growth cones and the cues that repel them
29. Collapsin: A protein in brain that induces the collapse and paralysis of neuronal growth cones
30. The molecular biology of axon guidance
31. 145
32. Neuropilin-2 is a receptor for semaphorin IV: Insight into the structural basis of receptor function and specificity
33. Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs
34. Neuropilin-semaphorin III/D-mediated chemorepulsive signals play a crucial role in peripheral nerve projection in mice
35. A requirement for neuropilin-1 in embryonic vessel formation
36. Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: Functional competition of collapsin-1 and vascular endothelial growth factor-165
37. Thymosin beta 15: A novel regulator of tumor cell motility upregulated in metastatic prostate cancer
38. Modulation of fibroblast growth factor-2 receptor binding, dimerization, signaling, and angiogenic activity by a synthetic heparin-mimicking polyanionic compound
39. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin
40. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation
41. Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1
42. Neuropilin-1 is a placenta growth factor-2 receptor
43. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors
44. Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton
45. Vascular endothelial growth factor stimulates Schwann cell invasion and neovascularization of acellular nerve grafts
46. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system
47. Neuropilin-1 is expressed on bone marrow stromal cells: A novel interaction with hematopoietic cells?
48. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and anti-tumor activity